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Abstract: Protein kinases play a critical role in cell regulation and their deregulation is a 
contributing factor in an increasing list of diseases including cancer. Marine sponges have 
yielded over 70 novel compounds to date that exhibit significant inhibitory activity towards 
a range of protein kinases. These compounds, which belong to diverse structural classes, 
are reviewed herein, and ordered based upon the kinase that they inhibit. Relevant 
synthetic studies on the marine natural product kinase inhibitors have also been included.  
Keywords: marine sponges; marine natural products; protein kinase inhibitors; cell 
regulation; anticancer agents 
 
1. Introduction 
The search for pharmaceutically active compounds from natural sources is well established, with 
approximately 70% of small molecule drugs produced between 1981 and 2006 possessing an important 
link to a natural product source [1]. The pharmaceutical value of natural products is even more 
exemplified in the critical area of anticancer drugs, whereupon of the 155 small-molecules produced 
from the 1940s, 73% are other than “synthetic”, with 47% being natural products or natural product 
derived [1]. With oceans covering 70% of the surface of the earth, coupled with the large and varied 
biodiversity of the marine environment, the oceans remain a largely unexplored, but extremely 
promising source of new drug candidates. Approximately half of the novel marine natural products 
reported in the literature are biologically active [2]. This occurrence can be contributed to the reliance 
of sessile, soft-bodied marine invertebrates on chemical defense for survival, as many lack the physical 
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defense mechanisms of movement and camouflage. As these chemicals are released into the water and 
are rapidly diluted, these secondary metabolites produced are often extremely potent [3].  
The protein kinase family encompasses all enzymes in the human body that catalyse the chemical 
transfer of a phosphate group from a high energy molecule such as adenine triphosphate (ATP) to a 
specific substrate. The human genome encodes for approximately 518 different protein kinases, which 
are divided into different kinase families on the basis of their selectivity for substrates [4]. The 
covalent attachment of a phosphate group to a substrate requires a free hydroxyl moiety, and there are 
three amino acids that can provide this; serine, threonine and tyrosine. Therefore, serine/threonine 
kinases will recognise and attach a phosphate group to a serine or threonine amino acid, while the 
tyrosine-specific protein kinase family will phosphorylate a protein at a tyrosine moiety.  
Kinases play a large, varied and vital role in cell regulation and particularly in signal transmission 
pathways, controlling cell differentiation, proliferation, metabolism, DNA damage repair, cell motility, 
response to external stimuli and apoptosis [5]. Deregulation of kinases has been found to be a primary 
cause in an increasing list of diseases, including oncological diseases, central nervous system 
disorders, autoimmune diseases, metabolic diseases and osteoporosis, suggesting that the number of 
kinases with the potential to be new pharmaceutical targets is significantly large [6]. The current focus 
on kinases is in the development of drugs with lower side effects than previous cancer treatments 
which traditionally focused on DNA replication and chromosome regulation and thus also affected 
many healthy cells. As various kinases have been reported to be misregulated in cancerous cells, 
anticancer treatments involving kinases can be specifically targeted to cancer cells  [4]. The 
development of kinase inhibitors has been predicted to be a major driver of pharmaceutical growth 
with more than 130 kinase inhibitors reported to be in either Phase I or Phase II clinical trials, the 
majority of these being tested for their potential as cancer treatments [7]. Kinase inhibitors that 
successfully proceed onto the pharmaceutical market will join Imitinib (Gleevec, Novartis), a tyrosine 
kinase inhibitor that has dramatically improved the prognosis for sufferers of chronic myeloid 
leukemia after being the first small-molecule kinase inhibitor to be approved for human use [6]. 
Herein, we review the recent highlights and developments of over 70 kinase inhibitors that have been 
isolated from marine sponges. 
2. Reviews 
Kinase inhibitors and activators from natural sources were covered in 2011 by Marston in a review 
that included a small number of marine natural products [8]. In 2007, Nakao and Fusetani published a 
review on enzyme inhibitors isolated from marine organisms which included some protein kinase 
inhibitors from marine sponges [9]. In 2009, Deslandes et al. reviewed the synthesis and kinase 
inhibitory activities of the marine natural products granulatimide and isogranulatimide [10]. In 2009, 
Nguyen et al. published the synthesis and evaluation of the kinase inhibitory activity of the sponge 
derived compound hymenialdisine and its analogues [11]. In 1998, Carter and Kane reviewed the 
therapeutic potential of natural compounds that regulate the activity of protein kinase C [12]. To the 
best of the authors’ knowledge, this is the first comprehensive review that is focussed solely on the 
kinase inhibitory activities of marine sponge metabolites. 
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3. Protein Kinase C (PKC, EC 2.7.11.13) 
The family of kinases known as protein kinase C (PKC) are serine/threonine kinases that 
encompass eleven isozymes and through the action of phosphorylating various intracellular proteins, 
mediate many physiological events such as induction of cell differentiation, regulation of apoptosis 
and inhibition of tumor invasion [13]. Protein kinase C is composed of two distinct regions; a 
carboxyl-terminal catalytic site containing an adenine triphosphate (ATP) binding site and a regulatory 
domain at the amino terminal that possesses a phorbol-binding domain that is unique to the PKC 
family [14]. The catalytic site on PKC is structurally shared amongst many different classes of kinases, 
and as such PKC inhibitors that block this site can also inhibit the action of other functionally diverse 
kinases [14]. Natural activators of PKC include diacylglycerols, phosphatidyl serine, inositol 
triphosphate and calcium ions. The vital role that PKCs play in signal transduction pathways has 
marked them as potential targets for pharmaceutical inhibition of diseases such as cancer, 
cardiovascular disease, renal disease, immunosuppression and autoimmune disease [15].  
The efficacy of the natural product staurosporine as a PKC inhibitor has been known since last 
century when the alkaloid was isolated from the bacteria Streptomyces staurosporeus and shown more 
recently to have an IC50 value of 2.7 nM against PKC [16]. In recent years, a variety of marine organisms 
have also provided important PKC modulators such as 11-hydroxystaurosporine from the marine 
tunicate  Eudistoma  sp.  [17] and bryostatin-1, from the marine bryozoan Bugula neritina [14,18]. 
Marine sponges have also proven to be a particularly rich source of PKC inhibitors.  
In 1994, the sponge Xestospongia sp. collected in waters off the Papua New Guinea coast, furnished 
xestocyclamine A (1, Figure 1) bearing a novel skeleton and found to inhibit PKC with an IC50 value 
of 4 μg/mL [19]. Xestocyclamine A and its pure enantiomer (−)-xestocyclamine A are considered critical 
PKC inhibitors for use in the development of anticancer drugs and there are many research groups 
focused on synthesising the stereochemically complex marine alkaloids [20,21]. (Z)-Axinohydantoin  
(2, Figure 1) and debromo-Z-axinohydantoin (3, Figure 1) are two PKC inhibitors with respective IC50 
values of 9.0 and 22.0 μM that were isolated from the marine sponge Stylotella aurantium [22]. These 
novel compounds were isolated during a scale-up collection of the PKC inhibitors, hymenialdisine  
(4, IC50 0.8 μM, Figure  1) and debromohymenialdisine (5, IC50 1.3 μM, Figure  1) from the same 
sponge species [22]. Hymenialdisine is found to inhibit a range of kinases (see Section 4.1). 
Five novel sesquiterpene derivatives, frondosins A–E (6–10, Figure 1), were isolated from the 
marine sponge Dysidea frondosa and shown to have inhibitory activity against PKC with reported IC50 
values of 1.8, 4.8, 20.9, 26.0 and 30.6 μM respectively [23]. Frondosins A–E were also reported to be 
inhibitors of interleukin-8 in the low micromolar range [23] and more recently (−)-frondosins A (6) 
and D (9) have shown comparable activity against the HIV virus [24]. Various synthetic routes to 
frondosins A–C have been reported [25–27]. 
BRS1 (11, Figure 1), a polyunsaturated lipid isolated from an unidentified Australian sponge of 
class Calcarea was reported to be a novel inhibitor of PKC [28]. BRS1 exerts it activity by binding to 
the phorbol ester binding site and accounts for 0.02% of the wet weight of the sponge from which it 
was collected. The IC50 of BRS1 for inhibiting the binding of the phorbol ester was 9 μM, whereas 
98 μM represented a 50% effective concentration for inhibiting the enzymatic activity of PKC [28]. 
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Figure 1. Protein kinase C inhibitors isolated from marine sponges. 
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An Okinawan marine sponge belonging to the family Spongiidae, has furnished a family of novel 
sesquiterpenoid quinones, including the nakijiquinones A–D (12–15, Figure 1), with reported IC50 
values against PKC of 270, 200, 23 and 220 μM respectively [29,30]. A subsequent paper described 
the isolation of the nakijiquinones G–I (16–18) from the same sponge, which showed modest 
cytotoxicity in the range of 2.4 to >10 μg/mL against a range of cancer cell lines (e.g., P388 murine 
leukemia, L1210 murine leukemia and KB human epidermal carcinoma cells), as well as inhibitory 
activity against HER2 kinase [31]. The remarkable inhibitory activity of nakijiquinones A–D against a 
variety of kinases including epidermal growth factor receptor (EGFR), c-erbB-2 kinase and tyrosine 
kinase VEGFR2 has been reviewed and their biological activity and structure-activity relationships are 
well documented [15,32]. The synthesis of the nakijiquinones has been reported [33,34], with 
particular emphasis on the potential of nakijiquinone and its analogues in the prevention of 
angiogenesis as the nakijiquinone family is the only naturally occurring inhibitor of the Her-2/Neu 
receptor tyrosine kinase. Extensively implicated in tumor proliferation, the Her-2/Neu receptor 
tyrosine kinase is over-expressed in approximately 30% of primary breast, ovary and gastric cancers 
and when amplified has been linked to increases in the aggressiveness of the cancer and reduced 
patient survival [35]. 
The cytotoxic sesterpenes spongianolides A–E (19–23, Figure 1), isolated from a marine sponge 
belonging to the genus Spongia, were found to have inhibitory activity against PKC with IC50 values 
ranging between 20–30 μM [36]. The cheilanthane cyclic terpenoid contained within the structure has 
since been synthesized via a biomimetic approach [37] (see also Section 7). 
Another potent marine sponge derived PKC inhibitor is lasonolide A (24, Figure 1). Isolated from 
the Caribbean sponge Forcepia sp., lasonolide A was found to inhibit the phorbol ester-stimulated 
adherence of EL-4.IL-2 mouse thymoma cells within 30 min with an IC50 value of 27 nM, highlighting 
the potential of this compound for development as a potent PKC inhibitor [38–40]. 
Another inhibitor of PKC enzyme is a new azetidine compound penazetidine A (25, Figure 1) 
isolated from the Indo-Pacific marine sponge Penares sollasi [41].  This sponge species attracted 
attention after its crude extract in initial screenings exhibited inhibitory activity (IC50 0.3 µg/mL) 
against serine kinase PKC-βI, but it was not active against protein tyrosine kinase (PTK). Penazetidine 
A displayed strong activity against PKC (IC50 l µM), and also showed significant cytotoxicity against 
human and murine cancer cell lines (A549, HT-29, B16/F10 and P388) [41]. A mixture of two 
diastereomeric spirosesquiterpene aldehydes, corallidictyals A and B, were isolated from the marine 
sponge  Aka  (=Siphonodictyon) coralliphaga,  which was collected  at Little San Salvador Island   
(26, 27, Figure 1) [42]. This mixture was found to show good selectivity for the inhibition of PKC 
(IC50 28 µM) compared to the other serine kinase enzyme PKA (IC50 300 µM). In particular, the 
diastereomeric mixture was selective for inhibition of the α-PKC isoform giving a lower IC50 value 
compared to the other isoforms of the enzyme.  
4. Cyclin Dependent Kinases (CDK, EC 2.7.11.22) 
Cyclin-Dependent kinases (CDKs) are a group of serine/threonine kinases that encompass 
approximately 25 different cyclin families, all of which are critical in the regulation of the cell 
cycle  [4]. The distinguishing feature of the CDKs from other kinase families is the enzymatic Mar. Drugs 2011, 9  
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activation requirement of the binding of the cyclin regulatory subunit [43]. The movement of the cell 
through the cell cycle phases is determined by the fluctuating concentrations of different activated 
CDK/cyclin complexes whose cellular mechanism involves the phosphorylation of many distinct 
proteins at serine or threonine residues in specific sequences. While CDKs are also involved in 
apoptosis and transcription, their pivotal role in differentiation, transformation, proliferation and 
metastasis has recently seen CDKs become a major target for cancer therapies, especially now that it is 
recognized that hyperactive CDKs (overexpression) or hypoactive CDKs (mutation, deletion) are a 
leading cause of uncontrolled tumor proliferation in humans [4]. Several natural and synthetic 
compounds that inhibit CDKs in the sub-micromolar range have been isolated and are at various stages 
of clinical trials, the most advanced being flavopiridol, a semi-synthetically produced analogue of an 
alkaloid from the Indian tree Dyoxylum binectariferum, currently in Phase II clinical trials for soft 
tissue sarcomas [44]. These small molecule inhibitors arrest tumor proliferation and many are also 
capable of inducing apoptosis in proliferating cells [45].  
4.1. Cyclin Dependent Kinase-1 
Cyclin Dependent Kinase-1 (CDK-1) is a critical controller of the cell cycle in multi-cellular 
eukaryotic organisms and operates primarily in the mitosis (M) phase. In order for the cell to pass  
from the growth (G2) phase into M phase, activation of the CDK-1/cyclin B1 complex must be 
sustained in the nucleus from prophase into metaphase [46]. Hymenialdisine (4, Figure 1), a potent 
inhibitor of CDK-1, was first isolated in 1982 from the marine sponges Axinella verrucosa and 
Acanthella aurantiaca [47]. Hymenialdisine inhibits CDK-1/cyclin B (IC50 22 nM) through 
competitive inhibition at the ATP-binding site, and as this site is homologous with many kinase 
families, hymenialdisine also shows inhibitory activity against a variety of different kinases including 
CDK-2/cyclin A (IC50 70 nM), CDK-2/cyclin E (IC50 40 nM), CDK-5/p25 (IC50 28 nM), glycogen 
synthase kinase 3 (GSK-3) (IC50  10 nM) and creatine kinase 1 (CK1) (IC50 3 5  n M ) ,  w h i l e  s t i l l  
possessing good selectivity in vitro as inhibition of alternate molecular targets occurs at much higher 
IC50 values [48].  
Inhibition of the CDK-1/cyclin B complex has recently been shown to induce apoptosis in cells 
experiencing Myc (proto-oncogene) overexpression [49], a common phenomenon in many human 
cancers and a mechanism by which hymenialdisine and associated analogues could potentially act as 
anticancer agents. Many analogues of hymenialdisine that exhibit inhibitory activity against various 
CDKs in the nanomolar range have been successfully synthesized as medicinal chemists recognised 
the potential of hymenialdisine for use against many degenerative diseases [50]. Recent patents also 
highlight hymenialdisine and analogues as likely future pharmaceuticals for diseases such as asthma, 
rheumatoid arthritis, multiple sclerosis and Alzheimer’s disease due to its ability to arrest the NF-kappa 
B signaling process, a critical mechanism in the above diseases [51]. Microxine (28, Figure 2), a novel 
purine derivative, is an inhibitor of CDK-1, isolated from the Australian marine sponge genus 
Microxina, with an IC50 value of 13 μM against CDK-1 [52,53]. Variolin B (29, Figure 2) was isolated 
from the Antarctic sponge Kirkpatrickia varialosa, and it was found to display CDK inhibitory activity 
exhibiting selective inhibition towards CDK-1 and CDK-2 over CDK-4 and CDK-7 [53,54]. It was 
hypothesized that mechanism of action of variolin B is the inhibition of cyclin-dependent kinases that Mar. Drugs 2011, 9  
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interrupt the progression of the normal cell cycle. Variolin B inhibits the phosphorylation of 
histone H1 mediated by CDK-2/cyclin E, CDK-2/cyclin A, CDK-1/cyclin B, CDK-7/cyclin H, and 
CDK4/cyclin D, with IC50 values in the micromolar range [53]. Total synthesis of this compound has 
been performed by several research groups due to the vast biological potential of the compound with 
its antiviral and antitumor activity, including cytotoxicity towards the P388 murine leukemia cell line 
with an IC50 value of 210 ng/mL [53,55–58]. 
Figure 2. Cyclin dependant kinase inhibitors isolated from marine sponges. 
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4.2. Cyclin Dependent Kinase-4 
Another member of the CDK family is CDK-4, a catalytic subunit whose presence is vital for the 
progression of the cell cycle through the G1 phase [59]. The activity of CDK-4 is restricted to the G1-S 
phases and is regulated by the attachment of the regulatory subunit cyclin D and the endogenous CDK 
inhibitor p16(INK4a). The G1-S checkpoint is the most important regulation point in the cell cycle, 
exemplified by the fact that the G1-S transition is misregulated in 60–70% of cancers [60]. A major 
role of CDK-4 is the phosphorylation of the retinoblastoma gene product (Rb) [59]. A high incidence 
of mutations in Rb, along with cyclin D and p16(INK4a), has been seen in tumorigenesis in many 
cancers, a fact which has recently seen CDK-4 become an exciting new cancer drug target. 
A major distinguishing feature of fascaplysin (30, Figure 2), a red pigment isolated from the marine 
sponge Fascaplysinopsis sp. is that it is a selective inhibitor of CDK-4 [61]. Poor selectivity is a 
common problem among kinase inhibitors due to the ATP binding site, where many inhibitors exert 
their actions, being conserved amongst the majority of kinase families. Fascaplysin exhibits an IC50 
value of 0.35 μM against the CDK-4/cyclin D complex while IC50 values against other kinases were 
comparably much higher [61]. This specificity allows fascaplysin to be a useful scientific tool in Mar. Drugs 2011, 9  
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investigating the direct consequences of singular CDK-4 inhibition [61] and many studies have thus 
been conducted establishing the potential of fascaplysin as a pharmaceutical agent. A recent study has 
identified fascaplysin as a natural angiogenesis inhibitor after it was found that fascaplysin selectively 
inhibited the proliferation of endothelial cells toward tumor cells and suppressed the vascular 
endothelial growth factor (VEGF), a critical player in angiogenesis [60]. Conclusions from such 
studies indicate that fascaplysin could in the future play a central role in preventing cancers from 
metastasizing and becoming malignant by preventing new vascular growth at the tumor site [60]. 
Konbu’acidin A (31, Figure 2) is a novel bromopyrrole alkaloid that was isolated from the 
Okinawan marine sponge Hymeniacidon sp. and reported to display inhibitory activity against the 
CDK-4/cyclin D complex [62]. Konbu’acidin A showed inhibitory activity against CDK-4 with an 
IC50 of 20 μg/mL but did not show any cytotoxicity against murine leukemia L1210 and epidermal 
carcinoma KB cell lines [62]. The marine sponge Aka sp. collected from Micronesia yielded three 
novel sesquiterpene quinols (32–34), two known quinols (35, 36) and halistanol sulfate (37). Four of 
the compounds (32,  35–37) were screened for CDK/cyclin D1 kinase inhibitory activity and 
compounds 35 and 37 exhibited moderate kinase inhibitory activity and inhibited complex formation 
with IC50 values of 9.0 and 9.5 µg/mL respectively [63]. 
5. Tyrosine Protein Kinase (TPK, EC 2.7.10.1) 
Tyrosine protein kinase (TPK) are enzymes that catalyse the phosphorylation of tyrosine residues 
and can be divided into two main categories; cellular and receptor TPKs, and non-receptor TPKs. 
Studies into this particular class of kinase have identified them as key players in both intracellular and 
extracellular communication [64]. TPKs are associated with proliferative diseases such as cancer, 
leukemia, psoriasis and restonosis due to their role in regulating key cell functions like proliferation, 
differentiation, and antiapoptotic signaling [64] and it has been reported that 70% of the known 
oncogenes and proto-oncogenes found in cancer are associated with TPKs [65]. 
The deep-sea sponge Ircinia sp. collected off the New Caledonian coast at a depth of   
425–500 m yielded three TPK inhibitors, the penta-, hexa- and hepta-prenylhydroquinone 4-sulfates 
(38–40, Figure 3). IC50 values for each compound against TPK were recorded as 8, 4 and 8 μg/mL 
respectively [66]. Penta-prenylhydroquinone sulfate (38, Figure 3) has also proven to be a potential 
antiviral and cytotoxic agent achieving 65% inhibition of the HIV-1 integrase enzyme at 1 μg/mL and 
having inhibited neuropeptide Y (NPY) receptor with an IC50 value of 50.8 μg/mL. This compound 
also displayed cytotoxicity against the epidermal KB carcinoma cell line [66].  
Tyrosine Kinase pp60
V-SRC 
Tyrosine kinase pp60
V-SRC is a membrane-associated protein with protein kinase activity and is also 
the oncogene product of the Rous Sarcoma retrovirus, which upon entry into a cell, transforms a 
normal cell into a rapidly proliferating cell [67]. Melemeleone (41, Figure 3) is a novel sesquiterpene 
quinonecompound, isolated along with another four new metabolites and two known compounds, from 
two sponge species of Dysidea from Solomon Island [68]. All purified compounds isolated from the 
sponge were tested for kinase inhibitory activity, but only melemeleone displayed activity against 
pp60
V-SRC with an IC50 of 28 µM [68].  Mar. Drugs 2011, 9  
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Figure 3. Tyrosine protein kinase inhibitors isolated from marine sponges. 
 
Several inhibitors of pp60
V-SRC were isolated from the Fijian sponge Xestospongia carbonaria, 
namely halenaquinone (42, Figure 3), halenaquinol (44, Figure 3), halenaquinol sulfate (45, Figure 3) 
and xestoquinone (46, Figure 3), and reported IC50 values of 1.5, 60.0, 0.55 and 28.0  μM, 
respectively [69]. Of these pentacyclic polyketide compounds, halenaquinone proved to be the most 
pharmaceutically promising, due to its characterisation as an irreversible inhibitor. The potential of 
halenaquinone as an anticancer agent is evidenced by findings that it arrests the proliferation of various 
cell lines, including those that have been transformed by oncogenic PTKs, and halenaquinone also 
shows inhibitory activity against the kinase activity of the human EGFR with an IC50 value of   
19 μM [69]. Halenaquinone (42) and xestoquinone (46) were also isolated from the same sponge 
Xestospongia sp. collected from Vanuatu and were found to inhibit several kinases. Xestoquinone 
inhibited Pfnek-1 kinase of Plasmodium falciparum with IC50 of 1.1 µM but displayed lower kinase 
inhibitory activity towards PfPK5 and no activity towards PfPK7 and PfGSK-3 [70]. 
Halenaquinone and halenaquinol have since been associated with antibiotic and cardiotonic activity 
in addition to their ability to inhibit pp60
V-SRC, and have been the focus of several synthetic studies [71]. 
Strategies for the synthesis of the core skeletons of halenaquinone and halenaquinol have recently been 
described with the construction of the furan-fused tetracyclic core of the molecules. The key step 
involved the intramolecular [4 + 2]-cycloaddition reaction of o-quinodimethane [71]. The current 
highlight with halenaquinone is as its potential as an inhibitor of recombinant human Cdc25B 
phosphatase [72], an activator of cyclin dependent kinase Cdc2 whose presence is required for entry 
into the mitosis phase of the cell cycle. Displaying an IC50 value of 0.7 μM, halenaquinone stands out 
as a key molecule in anticancer studies revolving around this drug target [72]. Alvi et al. also isolated 
the two compounds 14-methoxyhalenaquinone (43, Figure 3) and xestoquinolide A (47, Figure 3) from 
the same sponge, for which IC50 values of 5 and 80  μM against protein tyrosine kinase (PTK) 
respectively were reported [73]. 
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6. Epidermal Growth Factor Receptor (EC 2.7.10.1) 
The epidermal growth factor receptor (EGFR) is a member of the type 1 growth factor receptor 
gene family, which also includes erbB-1, erbB-2, erbB-3 and erbB-4 [74]. This tyrosine kinase family 
has been heavily implicated in the mechanisms of various cancers as mutations leading to EGFR being 
over-expressed have often been found in cancer cases, in particular breast cancer [15]. As part of an 
extensive effort to identify small molecule inhibitors of this drug target, two novel bromopyrrole 
alkaloids were isolated from an Okinawan marine sponge Hymeniacidon sp. and named tauroacidins A 
and B (48, 49, Figure 4) [75]. These two compounds showed inhibitory activity against both EGFR 
and c-erbB-2 kinase with an IC50 value of 20 μg/mL for each respective kinase [75]. The tauroacidins 
A and B may be biogenetically related to other bromopyrrole alkaloids from marine sponges through 
the taurine residue attached to the aminoimidazole ring [75]. Okinawan marine sponges have proven  
to be a particularly rich source of kinase inhibitors with a bromotyrosine alkaloid, ma’edamine A  
(50, Figure 4), also being isolated from the Okinawan marine sponge Suberea sp. and showing 
inhibitory activity against c-erbB-2 kinase (IC50 6.7 μg/mL) [76]. Ma’edamine A contains a unique 
2(1H)pyrazinone moiety located between the two bromotyrosine units, and also displays cytotoxicity 
against murine leukemia L1210 cells (IC50 4.3  μg/mL) and epidermal KB carcinoma cells 
(IC50 5.2 μg/mL) [76]. 
Figure 4. Epidermal growth factor receptor inhibitors isolated from marine sponges. 
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Spongiacidins A and B (51,  52, Figure 4) are inhibitors of c-erbB-2 kinase isolated from the 
Okinawan marine sponge Hymenacidon sp. [77]. These two compounds are also bromopyrrole 
alkaloids of the pyrrolo[2,3-c]azepine type. The respective IC50 values for spongiacidins A and B 
against c-erbB-2 kinase are 8.5 and 6.0 μg/mL [77]. It was later identified that spongiacidin A is 
actually the (E) isomer at the exocyclic C10-C11 double bond of 3-bromohymenialdisine, a metabolite 
of hymenialdisine discussed earlier [78]. 
Isolated from the marine sponge species Verongia aerophoba, (+)-aeroplysinin-1 (53, Figure 4) was 
found to completely inhibit EGFR at a concentration of 0.5 μM [79]. Due to this inhibitory ability,  
(+)-aeroplysinin-1 was found to have a strong antitumor effect on EGFR tumor cell lines, in particular 
blocking the proliferation of EGFR dependent human breast cancer cell lines MCF-7 and ZR-75-1 
[79]. Importantly, (+)-aeroplysinin-1 displays some selectivity for cancerous cells as the application of 
(+)-aeroplysinin-1 at a concentration of 0.25–0.5 μM resulted in total tumor cell death, but did not 
have any cytotoxic effect on normal human fibroblasts at concentrations ten times higher [79]. A 
recent study has identified (+)-aeroplysinin-1 as an important inhibitor of several key steps of 
angiogenesis, the process by which tumors become mutagenic and thus a vital target for 
pharmaceutical intervention in cancerous diseases [80]. In detail, (+)-aeroplysinin-1 has been shown to 
inhibit capillary-like tube formation, induce apoptosis, promote anti-proteolysis in endothelial cells and 
also arrest the development of new vascular structures [80]. As angiogenesis is a major factor in fatal 
cancers and (+)-aeroplysinin-1 displays in vivo efficacy as an inhibitor of this process, it remains an 
extremely promising drug candidate. 
Three novel compounds identified as 3,9-dimethyldibenzo[b,d]furan-1,7-diol (54),  
3-(hydroxymethyl)-9-methyldibenzo[b,d]furan-1,7-diol (55), 1,7-dihydroxy-9-methyldibenzo[b,d] 
furan-3-carboxylic acid (56) and one known compound, butyrolactone derivative (57), were isolated 
from marine sponge Acanthella cavernosa from Fiji and all compounds displayed moderate inhibitory 
properties against EGFR [81]. In recent studies, bioassay-guided fractionation of the marine   
sponge Spongionella sp., yielded the novel bioactive diterpenes, 3′-norspongiolactone (58, Figure 4) 
and gracilins J–L (59–61), along with three known gracilins and the known diterpenoid 
tetrahydroaplysulphurin-1 [82]. All eight compounds isolated from the sponge Spongionella sp. 
exhibited cytotoxicity against the K562 human chronic myelogenous leukemia cell lines with IC50 
values in the range of 0.6 to 15 μM, however they also showed similar levels of cytotoxicity towards 
human peripheral blood mononuclear cells (PBMC) [82]. All compounds displayed inhibitory activity 
towards EGFR tyrosine kinase with the novel diterpenes 58–61 exhibiting 25%, 19%, 75% and 57% 
inhibition respectively at 100 μM [82]. 
7. Mitogen-Activated Protein Kinase (EC 2.7.11.24) 
Mitogen- and stress-activated kinase (MSK1) and mitogen-activated protein kinase (MAPK) are two 
stress-associated serine/threonine specific protein kinases involved in cellular signaling, regulating 
various processes such as cell division and proliferation, apoptosis and gene expression [83]. There are 
three major subclasses of this kinase family, including extracellular signal-regulated kinases (ERKs), 
c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPKs) and p38 MAPKs [83]. It has 
been acknowledged that selective inhibitors of these kinases are likely to affect cellular events with Mar. Drugs 2011, 9  
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high specificity and are therefore molecules of significant interest in the search for anticancer 
pharmaceuticals [15].  
In the first description of cheilanthane sesterterpenoids from a marine sponge, three novel (62–64) 
and one known cheilanthane sesterterpenoids (65, Figure 5) were isolated from the marine sponge 
Ircinia sp., with 62, 63 and 65 obtained as inseparable 1:1 mixtures of their C-25 epimers. Intriguingly, 
all four compounds were reported to exhibit identical inhibitory activity against MSK1 (IC50 4 μM for 
each compound) and mitogen activated protein kinase activated protein kinase (MAPKAPK-2, IC50 
90 μM for each compound) [84]. Extracts from two sponge species, the purple bleeding sponge 
Iotrochota birotulata and the West Indian bath sponge Spongia barbara were found to inhibit the 
MAPK/ERK cascade, a pathway that links the binding of growth factors on cell surface receptors to 
intracellular responses [85]. Encompassing many protein kinases, activation of this cascade leads to 
cell division and is thus a potential anticancer drug target [86]. The two extracts significantly inhibited 
the MAPK/ERK pathway to 51% and 44% of control levels respectively without affecting the survival 
of the cell [85].  
Figure 5. Mitogen-activated protein kinase inhibitors isolated from marine sponges. 
 
Raf (EC 2.7.11.1)/MAP Kinase Kinase (EC 2.7.12.2)/MAPK (EC 2.7.11.24) 
The Raf kinase, MAP kinase kinase (MEK) and MAPK combine to form a pathway that links 
extracellular signals to the phosphorylation of cellular proteins to regulate cell proliferation and Mar. Drugs 2011, 9  
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differentiation [87]. The cascade is firstly activated by Ras promoting the translocation of Raf-1 to the 
inner cell membrane where it undergoes phosphorylation for activation. Raf-1 specifically 
phosphorylates and activates MEK, which will continue the process by phosphorylating MAPKs, 
causing them to migrate into the nucleus of the cell and influence many cellular events [87]. The 
oncogenic form of Ras is implicated in over 30% of all cancers, and as the Raf/MEK/MAPK cascade 
contains many potential sites for inhibition, this is an important and extremely promising target to be 
studied for pharmaceutical intervention [87]. 
While it has been known for some time that hymenialdisine (4, Figure 1) shows significant 
inhibitory activity against many cellular kinases, it has recently been reported that hymenialdisine and 
debromohymenialdisine (5, Figure 1) are remarkably potent inhibitors of MEK with IC50 values of  
3.0 and 6.0 nM respectively [87]. These two compounds, isolated from the marine sponge Stylotella 
aurantium arrest the Raf/MEK/MAPK cascade by specifically binding to and inhibiting the 
phosphorylation of MAPK by MEK-1. It is also believed that 10E-hymenialdisine spontaneously 
converts to 10Z-hymenialdisine (4, Figure 1) on standing [87] and the mixture of these two compounds 
was shown to have the ability to inhibit the growth of LoVo and Caco-2, two human colon tumor  
cell lines [87]. 10Z-Hymenialdisine is now extensively used in research programs and is readily 
available from biochemical product suppliers as it shows good efficacy in vivo and has significant 
potential in a variety of different disease types as discussed earlier. Also extracted from the same 
sponge species was hymenin (59, Figure 5), which also showed inhibitory activity against the 
Raf/MEK/MAPK cascade [87]. However, with IC50 values ranging from between 128.8 and 250.0 μM 
for the different specific Raf, MEK and MAPK kinases, hymenin was far less potent than   
10E-hymenialdisine and 10Z-hymenialdisine and was not pursued any further [87].  
A methanol fraction of the sponge Batzella sp. was found to inhibit Raf kinase with an IC50 value of 
2.8 μg/mL [88]. The known antimitotic compound halitoxin [89] was identified, however, it was not 
responsible for the observed kinase inhibitory activity.  
Onnamide A (67) and theopederin B (68) are two compounds that were recently found to induce the 
stress-activated protein kinases, p38 kinase and JNK [90], two of the subclasses of the MAPK kinase 
family (Figure 5). While full understanding of the role of JNK in apoptosis has not yet been achieved, 
it is known that JNK and p38 kinase are predominantly activated by environmental stresses [91]. The 
JNK pathway is critical in the regulation of apoptosis during early brain development in mice and the 
p38 MAPK pathway plays a vital role in the production of inflammatory cytokines and subsequent 
signaling and also appears to be heavily associated with cell survival and proliferation [91]. Onnamide 
A and theopederin B, heterocyclic compounds that are members of the pederin family isolated from a 
marine sponge, activate a ribotoxic stress response and induce apoptosis [90,92,93]. As well as 
inducing the production of p38 and JNK, these two compounds were also found to stimulate 
plasminogen activator inhibitor-1 (PAI-1) gene expression in concentration ranges of 10–100 nM for 
onnamide A and 1–10 nM for theopederin B [90]. PAI-1 is an important current drug target as high 
levels of PAI-1 have consistently been found in human cancer cells and PAI-1 has also been associated 
with tumor growth, invasion and metastasis [94]. Thus, onnamide A and theopederin B will provide 
important tools in understanding more about PAI-1 expression and the induction of the ribotoxic stress 
response [90]. (+)-Makassaric acid (69) and (+)-subersic acid (70) are novel meroterpenoid compounds, Mar. Drugs 2011, 9  
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isolated from the sponge Acanthodendrilla sp. collected in Indonesia. These compounds were found to 
inhibit MAPKAP kinase 2 which is involved in stress and inflammatory responses [95]. 
8. Glycogen Synthase Kinase-3 (GSK-3, EC 2.7.11.26) 
A serine/threonine protein kinase, the main function of glycogen synthase kinase-3 (GSK-3) is the 
mediation of glycogen synthase but it is also involved in several key cellular events such as the 
response to damaged DNA and the phosphorylation of the microtubule associated mammalian protein 
tau. Overactivity of this phosphorylation has been identified as one of the first events in the onset of 
neurodegenerative diseases such as Alzheimer’s disease [96]. Over the last two decades, interest in 
GSK-3 has exponentially increased as its potential as a drug target in many non-curable diseases such 
as type-2 diabetes, stroke, Alzheimer’s disease, and bipolar disorder is recognized [96]. Current small 
molecule inhibitors of GSK-3 include pyridyloxadiazoles, thiadiazolidindiones, pyrazolopyrimidines 
and maleimides [96], but marine sponges are also proving to be a reliable source of secondary 
metabolites showing inhibitory activity against this drug target.  
Manzamine A (71, Figure 6), a complex alkaloid isolated from an Okinawan sponge of the genus 
Haliclona, is one such compound showing specific non-competitive inhibition of ATP binding in 
GSK-3β with an IC50 value of 10.2 μM [96]. Manzamine A also inhibits CDK-5 with an IC50 value of 
1.5  μM, and as this kinase coupled with GSK-3 represents the two main players in the 
hyperphosphorylation mechanism in Alzheimer’s disease, manzamine A is a useful drug lead for the 
future treatment of this disease [96]. This conclusion is supported by the fact that manzamine A has 
proved capable of entering cells and interfering with the tau protein as well as causing arrest in the 
hyperphosphorylation in human neuroblastoma cell lines [96]. Structure-activity relationships between 
manzamine A and the GSK-3 pharmacophore have been carried out and a variety of manzamine A 
analogues have also been synthesized indicating that the entire manzamine molecule is required for 
GSK-3 inhibitory activity [96]. Manzamine A and its synthesized derivative (−)-8-hydroxymanzamine 
A, have also been identified as promising new antimalarial agents producing in vivo inhibition of the 
growth of the malaria parasite Plasmodium berghei in rodents [97]. As the malaria parasite rapidly 
achieves resistance to currently administered antimalaria drugs, patents for the use of manzamine A in 
human antimalarial drugs have been submitted [98]. 
Figure 6. Glycogen synthase kinase-3 inhibitors isolated from marine sponges. 
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The carteriosulfonic acids A–C (72–74, Figure 6), novel compounds containing a   
4,6,7,9-tetrahydroxylated decanoic acid subunit, were recently identified during a screen to identify 
modulators of Wnt signaling, which plays a key role in cell proliferation [99]. Phosphorylation of  
β-catenin by GSK-3β is involved in the negative regulation of Wnt signaling and thus it was proposed 
that inhibitors of GSK-3β may be associated with Wnt signaling activation. Accordingly, the 
compounds (72–74) were isolated from an extract of the marine sponge Carteriospongia sp., which 
was a Wnt signaling activator and were found to be low micromolar inhibitors of GSK-3β. Although 
further biological studies were foreshadowed in the above article, they had not yet appeared at the time 
of writing this review [99].  
9. Other Kinases 
Liphagal (75, Figure 7), a meroterpenoid isolated from the marine sponge Aka coralliphaga collected 
in Dominica, was found to exhibit inhibitory activity against PI3K (phosphoinositide-3-kinase) with an 
IC50 value of 100 nM, with 10 folder higher potency against PI3Kα than towards PI3Kγ [100,101]. 
This compound also exhibited cytotoxicity against human colon (IC50 0.58 µM) and human breast 
(1.58 µM) tumor cell lines [100]. This sponge species is also known to produce the PKC inhibitors 
corallidictyals A and B (26 and 27) (see Section 3). Two bisabolene type sesquiterpenoids,   
(+)-curcuphenol (76, Figure 7) and (+)-curcudiol (77, Figure 7) were identified as bioactive compounds 
from the sponge Axynissa sp. from Indonesia. Curcuphenol showed Src protein kinase inhibition with 
an IC50 value of 7.8 µg/mL, while curcudiol inhibited focal adhesion kinase (FAK) with an IC50 value 
of 9.2 µg/mL [102]. Protein kinase A inhibitory activities of up to 100% (at 100 µg/mL) along with 
haemolytic and brine shrimp activities were also observed in a range of extracts isolated from three 
deep-water sponges collected from North Western Australia [103]. A novel compound, homogentisic 
acid (78) was isolated from the sponge Pseudoceratina  collected in Vanuatu [104]. The authors 
previously isolated xestoquinone from a Xestospongia sp. collected from the same place and in their 
research for new antimalarial drugs found that this compound was an inhibitor of Pfnek-1, which is a 
NIMA-related protein kinase of Plasmodium falciparum. Therefore homogentisic acid was also 
screened against Pfnek-1 and found to display an IC50 value of 1.8 µM against this target [104] 
Hymenialdisine (4) has also showed Polo-Like kinase-1 inhibitory activity of 10 µM. It was isolated 
along with debromohymenialdisine (5) and four novel dihydrohymenialdisine derivatives from the 
sponge Cymbastela cantharella [105]. 
Figure 7. Inhibitors of PI3K, Src, and focal adhesion kinase isolated from marine sponges. 
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There are several aspects to consider regarding kinase inhibitors such as whether they are   
ATP-competitive or non-competitive inhibitors and whether the compounds inhibit their reported 
enzymatic targets in cellular assays. However, the level of mechanistic detail and characterization of 
the kinase inhibitory activity of the compounds described herein varies greatly. Thus, herein those 
articles providing a higher degree of characterization are indicated in the Table 1 by an asterisk. A 
further issue is one of broader kinase selectivity profiling that would be useful to see addressed in the 
literature, both in terms selectivity of the inhibitors towards other kinases and towards other targets. 
Table 1. Various kinase inhibitors isolated from marine sponges. 
Kinase  Sponge species  Natural product (or compound type) 
IC50 (μM) 
₤  
(or % inhibition) 
Ref. 
PKC  Xestospongia sp.  Xestocyclamine A (1) 10  [19] 
  Stylotella aurantium  Axinohydantoins (2, 3) 9–22  [22] 
  Stylotella aurantium  Hymenialdisines (4, 5) 0.8–1.3  [22] 
  Dysidea frondosa  Frondosins A–E (6–10) 2–31    [23] 
 Class Calcarea  BRS 1 (11) 98    [28]  * 
 Family  Spongiidae  Nakijiquinones A–D, G–I (12–18) 23–270    [29,30] 
  Spongia sp. Spongianolides  A–E  (19–23) 20–30   [36] 
  Forecpia sp.  Lasonolide A (24) 0.03  [38,40]  * 
  Penares sollesi  Penazetidine A (25) 1  [41] 
  Aka coralliphaga  Corallidictyals A and B (26, 27) 28  [42] 
CDK  Axinella verrucosa  Hymenialdisine (4) 0.02    [48]  * 
  Microxina sp.  Microxine (28) 13    [52] 
  Kirkpatrickia varialosa  Variolin B (29) 0.03  [53]  * 
  Fascaplysinopsis sp.  Fascaplysin (30) 0.4    [61]  * 
  Hymeniacidon sp.  Konbu’acidin A (31) 27  [62] 
  Aka sp.  Quinol derivative (34) 0.019  [63] 
  Aka sp.  Halistanol sulfate (37) 0.013  [63] 
TPK  Ircinia sp.  Prenylhydroquinone 4-sulfates (38–40) 7–15  [66] 
  Dysidea sp.  Melemeleone B (41) 28  [68] 
  Xestospongia sp.  Halenoquinone (42, 43) 1.5–5  [69,73]  * 
  Xestospongia sp.  Halenaquinols (44, 45) 0.6–60    [69]  * 
  Xestospongia sp.  Xestoquinone (46) 28  [69]  * 
  Xestospongia sp.  Xestoquinolide A (47) 80    [73]  * 
EGFR  Hymeniacidon sp.  Tauroacidins A–B (48, 49) 38–45  [75] 
  Suberea sp.  Ma’edamine A (50) 11  [76] 
  Hymeniacidon sp.  Spongiacidins A–B (51, 52) 19–21 [78] 
  Verongia aerophoba  Aeroplysinin-1 (53) 0.5  [79] 
  Acanthella cavernosa  Dibenzofurandiols (54–57)  33–59 
† [81] 
  Spongionella sp.  3′-Norspongiolactone (58)  25 
† [82] 
  Spongionella sp.  Gracilins J–L (59–61)  19–75 
† [82] 
MAPK  Ircinia sp. Cheilanthene  sesterpenoids  (62–65) 4–90  [84] 
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Table 1. Cont. 
Raf/MAP  Stylissa massa  Hymenialdisines (4, 5) 0.003–0.006  [87]  * 
  Stylotella aurantium Hymenin (66) 129  [87]  * 
  Theonella sp.  Theopederin B (68) - 
‡ [90,92]  * 
  Theonella sp.  Onnamide A (67) - 
‡ [90,93]  * 
  Acanthodendrilla sp.  (+)-Makassaric acid (69)   20  [95] 
  Acanthodendrilla sp.  (+)-Subersic acid (70) 9.6  [95] 
GSK-3  Haliclona sp.  Manzamine A (71) 10    [96]  * 
 Unidentified  sp.  Glycerol lipids (72–74) 0.1–0.4    [99] 
Others  Aka coralliphaga  Liphagal (75)  0.1  [100,101]
  Axynissa sp.  (+)-Curcuphenol (76) 36  [102] 
  Axynissa sp.  (+)-Curcudiol (77) 37  [102] 
  Pseudoceratina sp.  Homogentisic acid (78) 1.8  [104] 
₤ Values reported in µg/mL were converted to µM; 
† % Inhibition at 100 µM; 
‡ Induces activation of p38 and JNK; * An 
asterisk denotes articles containing detailed characterisation of the kinase inhibitory activity.  
10. Conclusions 
The search for kinase inhibitors from marine sources has proven extremely successful with the 
advent of compounds such as bryostatin-1 into pharmaceutical development, and others such as 
hymenialdisine (4) and manzamine (71) looking promising. In particular, marine sponges are a rich 
source of highly diverse chemical compounds including lipids, terpenes and alkaloids, enhanced by a 
high incidence of novel carbon skeletons, such as that of xestocyclamine A (1). Marine sponge 
metabolites have proven to be extremely potent against a range of kinase targets heavily involved in an 
increasing list of disease mechanisms including cancer, Alzheimer’s disease and atherosclerosis. 
Several kinase inhibitors such as fascaplysin (30) possess strong selectivity not only for specific kinase 
subtypes, but also for cancerous cells over healthy cells and are thus promising molecules in the 
development of new oncological pharmaceuticals. With new technological developments bringing access 
to previously unexplored marine environments such as the deep sea [106], it is certain that many more 
sponge metabolites with novel structures and potent kinase inhibitory activities will be discovered in the 
future. Furthermore, as our understanding of the mechanism and regulation of various kinases 
continues to grow, marine sponge-derived kinase inhibitors are destined to play an expanding role in 
the treatment of various diseases. 
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